ArticleHemaSphere2019
SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1.
Article in HemaSphere, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Recent Advances in Research on Iron Metabolism, Ferritin, and Hepcidin.International journal of molecular sciences · 2026Pooled it
- Therapeutic Silencing of Tmprss6 Reduces Iron-Induced Inflammation and Prolongs Survival in MDS Mice.American journal of hematology · 2026Article
- Haemochromatosis - a modern clinician's guide.Internal medicine journal · 2026Review
- Metal Ion Signaling in Biomedicine.Chemical reviews · 2025Review
- Current Landscape of Hepcidin Therapeutics.Advances in experimental medicine and biology · 2025Review
- Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects.Signal transduction and targeted therapy · 2024Review
- Skin complications during iron chelation therapy for beta-thalassemia: overview and treatment approach.International journal of hematology · 2024Review
- The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis.HemaSphere · 2024Article
- RationalJournal of medicinal chemistry · 2024Article
- Interpreting Iron Homeostasis in Congenital and Acquired Disorders.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Targeted delivery of oligonucleotides using multivalent protein-carbohydrate interactions.Chemical Society reviews · 2023Review
- Hepcidin and Iron in Health and Disease.Annual review of medicine · 2023Review
- The Role of Iron in Benign and Malignant Hematopoiesis.Antioxidants & redox signaling · 2021Review
- Iron metabolism: pathophysiology and pharmacology.Trends in pharmacological sciences · 2021Review
- Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH.Journal of hepatology · 2021Article
- SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.British journal of haematology · 2021Article
- RNA Therapeutics - Research and Clinical Advancements.Frontiers in molecular biosciences · 2021Review
- Cutting not the key to TMPRSS6 activity?Blood · 2020Article
- Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.